Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
Q07817 |
B2CL1_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q07817 |
B2CL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q07817 |
B2CL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07817 |
B2CL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07817 |
B2CL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07817 |
B2CL1_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
Q07820 |
MCL1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q07820 |
MCL1_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q07820 |
MCL1_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Melanoma [ICD-11: 2C30] |
Q07820 |
MCL1_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
Q07820 |
MCL1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
Q07820 |
MCL1_HUMAN |
Asthma [ICD-11: CA23] |
Q07820 |
MCL1_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q07820 |
MCL1_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q07820 |
MCL1_HUMAN |
Malignant intestine neoplasm [ICD-11: 2C0Z] |
Q07820 |
MCL1_HUMAN |
Mastocytosis [ICD-11: 2A21] |
Q07820 |
MCL1_HUMAN |
Mature B-cell lymphoma [ICD-11: 2A85] |
Q07820 |
MCL1_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |